A New RA Approval (8.1.2025)
Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.
Read ArticleDr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.
Read ArticleDr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.
Read ArticleA target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis.
Read ArticleNew survey data from the Orlando Health Spine Center reveals a significant difference among Americans on how to manage neck and back pain. Respondents were split between relying on rest and reduced activity (44%), turning to over-the-counter pain
Read ArticleCurrent CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA. Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).
This most recent analysis of the prevalence and distribution of arthritis subtypes
Read ArticleDr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
Read ArticleThe American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.
Read ArticleDr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read ArticleKnee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of the First People’s Hospital of Neijiang, China.
Knee
Read ArticleJiha Lee @JihaRheum( View Tweet )
Aurelie Najm @AurelieRheumo( View Tweet )
Mrinalini Dey @DrMiniDey( View Tweet )
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.